FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides Lack Reliable Safety Information, Watchdog Warns FDA moves toward easing restrictions on certain peptides BioPharma Dive